1
|
Zeng Q, Lu W, Deng Z, Zhang B, Wu J, Chai J, Chen X, Xu X. The toxin mimic FS48 from the salivary gland of Xenopsylla cheopis functions as a Kv1.3 channel-blocking immunomodulator of T cell activation. J Biol Chem 2022; 298:101497. [PMID: 34919963 PMCID: PMC8732088 DOI: 10.1016/j.jbc.2021.101497] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 11/14/2021] [Accepted: 12/10/2021] [Indexed: 11/29/2022] Open
Abstract
The Kv1.3 channel has been widely demonstrated to play crucial roles in the activation and proliferation of T cells, which suggests that selective blockers could serve as potential therapeutics for autoimmune diseases mediated by T cells. We previously described that the toxin mimic FS48 from salivary gland of Xenopsylla cheopis downregulates the secretion of proinflammatory factors by Raw 264.7 cells by blocking the Kv1.3 channel and the subsequent inactivation of the proinflammatory MAPK/NF-κB pathways. However, the effects of FS48 on human T cells and autoimmune diseases are unclear. Here, we described its immunomodulatory effects on human T cells derived from suppression of Kv1.3 channel. Kv1.3 currents in Jurkat T cells were recorded by whole-cell patch-clamp, and Ca2+ influx, cell proliferation, and TNF-α and IL-2 secretion were measured using Fluo-4, CCK-8, and ELISA assays, respectively. The in vivo immunosuppressive activity of FS48 was evaluated with a rat DTH model. We found that FS48 reduced Kv1.3 currents in Jurkat T cells in a concentration-dependent manner with an IC50 value of about 1.42 μM. FS48 also significantly suppressed Kv1.3 protein expression, Ca2+ influx, MAPK/NF-κB/NFATc1 pathway activation, and TNF-α and IL-2 production in activated Jurkat T cells. Finally, we show that FS48 relieved the DTH response in rats. We therefore conclude that FS48 can block the Kv1.3 channel and inhibit human T cell activation, which most likely contributes to its immunomodulatory actions and highlights the great potential of this evolutionary-guided peptide as a drug template in future studies.
Collapse
Affiliation(s)
- Qingye Zeng
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
| | - Wancheng Lu
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
| | - Zhenhui Deng
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
| | - Bei Zhang
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
| | - Jiena Wu
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
| | - Jinwei Chai
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
| | - Xin Chen
- Department of Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China
| | - Xueqing Xu
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
| |
Collapse
|
2
|
Shimoura N, Nagai H, Fujiwara S, Jimbo H, Yoshimoto T, Nishigori C. Interleukin (IL)-18, cooperatively with IL-23, induces prominent inflammation and enhances psoriasis-like epidermal hyperplasia. Arch Dermatol Res 2017; 309:315-321. [DOI: 10.1007/s00403-017-1735-2] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2016] [Revised: 02/16/2017] [Accepted: 03/08/2017] [Indexed: 01/05/2023]
|
3
|
Zhong TY, Arancibia S, Born R, Tampe R, Villar J, Del Campo M, Manubens A, Becker MI. Hemocyanins Stimulate Innate Immunity by Inducing Different Temporal Patterns of Proinflammatory Cytokine Expression in Macrophages. THE JOURNAL OF IMMUNOLOGY 2016; 196:4650-62. [PMID: 27183578 DOI: 10.4049/jimmunol.1501156] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/19/2015] [Accepted: 03/24/2016] [Indexed: 12/20/2022]
Abstract
Hemocyanins induce a potent Th1-dominant immune response with beneficial clinical outcomes when used as a carrier/adjuvant in vaccines and nonspecific immunostimulant in cancer. However, the mechanisms by which hemocyanins trigger innate immune responses, leading to beneficial adaptive immune responses, are unknown. This response is triggered by a proinflammatory signal from various components, of which macrophages are an essential part. To understand how these proteins influence macrophage response, we investigated the effects of mollusks hemocyanins with varying structural and immunological properties, including hemocyanins from Concholepas concholepas, Fissurella latimarginata, and Megathura crenulata (keyhole limpet hemocyanin), on cultures of peritoneal macrophages. Hemocyanins were phagocytosed and slowly processed. Analysis of this process showed differential gene expression along with protein levels of proinflammatory markers, including IL-1β, IL-6, IL-12p40, and TNF-α. An extended expression analysis of 84 cytokines during a 24-h period showed a robust proinflammatory response for F. latimarginata hemocyanin in comparison with keyhole limpet hemocyanin and C. concholepas hemocyanin, which was characterized by an increase in the transcript levels of M1 cytokines involved in leukocyte recruitment. These cytokine genes included chemokines (Cxcl1, Cxcl3, Cxcl5, Ccl2, and Ccl3), ILs (Il1b and Ifng), growth factors (Csf2 and Csf3), and TNF family members (Cd40lg). The protein levels of certain cytokines were increased. However, every hemocyanin maintains downregulated key M2 cytokine genes, including Il4 and Il5 Collectively, our data demonstrate that hemocyanins are able to trigger the release of proinflammatory factors with different patterns of cytokine expression, suggesting differential signaling pathways and transcriptional network mechanisms that lead to the activation of M1-polarized macrophages.
Collapse
Affiliation(s)
- Ta-Ying Zhong
- Fundación Ciencia y Tecnología para el Desarrollo, Santiago 7750269, Chile; and
| | - Sergio Arancibia
- Fundación Ciencia y Tecnología para el Desarrollo, Santiago 7750269, Chile; and
| | - Raimundo Born
- Fundación Ciencia y Tecnología para el Desarrollo, Santiago 7750269, Chile; and
| | - Ricardo Tampe
- Fundación Ciencia y Tecnología para el Desarrollo, Santiago 7750269, Chile; and
| | - Javiera Villar
- Fundación Ciencia y Tecnología para el Desarrollo, Santiago 7750269, Chile; and
| | - Miguel Del Campo
- Fundación Ciencia y Tecnología para el Desarrollo, Santiago 7750269, Chile; and
| | | | - María Inés Becker
- Fundación Ciencia y Tecnología para el Desarrollo, Santiago 7750269, Chile; and Biosonda Corporation, Santiago 7750269, Chile
| |
Collapse
|
4
|
Ebrahimnezhad S, Amirghofran Z, Karimi MH. Decline in Immunological Responses Mediated by Dendritic Cells in Mice Treated with 18α-Glycyrrhetinic Acid. Immunol Invest 2016; 45:191-204. [DOI: 10.3109/08820139.2015.1113425] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
5
|
Li T, Wang W, Zhao JH, Zhou X, Li YM, Chen H. Pseudolaric acid B inhibits T-cell mediated immune response in vivo via p38MAPK signal cascades and PPARγ activation. Life Sci 2014; 121:88-96. [PMID: 25497712 DOI: 10.1016/j.lfs.2014.11.020] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2014] [Revised: 11/03/2014] [Accepted: 11/26/2014] [Indexed: 11/25/2022]
Abstract
AIMS Pseudolaric acid B (PAB) has been prescribed for its potent immunomodulatory effect. However, the detail of mechanism remains to be demonstrated. The purpose of this study is to further clarify the mechanism of PAB on T-cell mediated immune response in vivo. MAIN METHODS Investigations were carried to ascertain the pharmacological effect of PAB in a delayed-type hypersensitivity (DTH) mouse model of T-cell mediated immune response. Histological assessment was examined by hematoxylin and eosin staining. Affymetrix GeneChip® Mouse Genome 430 2.0 arrays were employed to evaluate the expression profile of PAB. Western blot was performed to detect p38MAPK signal cascades, including p38MAPK, ATF-2, MK2, and HSP27. Finally, TNF-α level was analyzed by ELISA, and Jurkat T cells were treated with PAB to determine its role on PPARγ activation using a reporter gene assay. KEY FINDINGS The results showed that PAB (5, 10, and 20mg/kg) could lead to a marked improvement for ear swelling and inflammatory infiltrate in DTH mice dose-dependently. According to the associated biological pathways from microarray analysis, PAB resulted in the restoration of abnormal immune-related gene expression linked to MAPK and PPAR signaling pathways. Moreover, PAB inhibited the activation of p38MAPK, ATF-2, MK2, and HSP27 significantly, as well as the production of TNF-α, which was reversed by GW9662, a specific antagonist for PPARγ. In addition, treatment with PAB also increased the transcriptional activity of PPARγ in a dose-dependent manner. SIGNIFICANCE These results provide us with novel insights into pharmacological action of PAB as a potential immunomodulator for the treatment of immune-related diseases.
Collapse
Affiliation(s)
- Tan Li
- Department of Pathogen Biology and Immunology, Logistics University of the Chinese People's Armed Police Force, Tianjin, PR China; Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury, Logistics University of the Chinese People's Armed Police Force, Tianjin, PR China.
| | - Wei Wang
- Pingjin Hospital, Logistics University of the Chinese People's Armed Police Forces, Tianjin, PR China
| | - Ji-hong Zhao
- Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury, Logistics University of the Chinese People's Armed Police Force, Tianjin, PR China; Pingjin Hospital, Logistics University of the Chinese People's Armed Police Forces, Tianjin, PR China
| | - Xin Zhou
- Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury, Logistics University of the Chinese People's Armed Police Force, Tianjin, PR China; Pingjin Hospital, Logistics University of the Chinese People's Armed Police Forces, Tianjin, PR China
| | - Yu-ming Li
- Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury, Logistics University of the Chinese People's Armed Police Force, Tianjin, PR China
| | - Hong Chen
- Department of Pharmacognosy and Pharmaceutics, Logistics University of the Chinese People's Armed Police Force, Tianjin, PR China; Tianjin Key Laboratory for Prevention and Control of Occupational and Environmental Hazard, Logistics University of the Chinese People's Armed Police Force, Tianjin, PR China.
| |
Collapse
|
6
|
Banday AH, Jeelani S, Hruby VJ. Cancer vaccine adjuvants--recent clinical progress and future perspectives. Immunopharmacol Immunotoxicol 2014; 37:1-11. [PMID: 25318595 DOI: 10.3109/08923973.2014.971963] [Citation(s) in RCA: 69] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Despite recent breakthroughs in the prognosis, prevention and treatment, cancer still remains the leading cause of death and affects millions of people worldwide. With the US FDA approval of various preventive cancer vaccines such as Gardasil (Merck), Cervarix (Glaxosmithkline) and the therapeutic vaccine Sipulencel-T (Provenge), cancer vaccine development is gaining huge ground. Approval of these vaccines has encouraged the concept of cancer treatment through cellular immunotherapy. The FDA approval of the above vaccines has provided support for renewed interest and attention which the development of new therapeutic cancer vaccines deserves. However, most of the new generation vaccines including that for cancer are poorly immunogenic sub-unit vaccines and thus essentially need adjuvants in their formulations to compensate for the immune suppression. Adjuvants are the essential components of a potent vaccine which increases the efficacy by enhancing the antigen-specific immune response. However, the design of a successful adjuvant is not easy because of the complexity and the difficulty in designing adjuvants that are safe, potent and economically viable. The present communication takes a short review of the advancements in adjuvant technology, current clinical scenario of new adjuvants and application of their molecularly defined formulations to new generation cancer vaccines which are currently under development.
Collapse
Affiliation(s)
- Abid H Banday
- Department of Chemistry and Biochemistry, University of Arizona , Tucson, AZ , USA
| | | | | |
Collapse
|
7
|
Abstract
Delayed-type hypersensitivity (DTH) is a useful approach for evaluating cell-mediated immune responses associated with Th1 reactivity. The DTH reaction is divided into the afferent and efferent phases. During the afferent phase of this model, mice are typically immunized by subcutaneous injection with a specific hapten or antigen in its chemically reactive state and emulsified with an adjuvant. The efferent phase is typically initiated 5-12 days after sensitization, whereby the previously sensitized mice are challenged by either subcutaneous footpad injection or intradermal ear injection. The DTH response is evaluated 24 h post challenge. Here, we describe a common protocol for the induction and assessment of the DTH reaction in mice using keyhole limpet hemocyanin.
Collapse
|
8
|
Abstract
The recent FDA approval of sipuleucel-T (Provenge), a patient-specific immunotherapy for androgen-independent prostate cancer developed by Dendreon Corporation, has provided support for the concept of cellular immunotherapy as an approach to cancer treatment. Adjuvants are compounds that enhance the potency of the antigen-specific immune response and can be an essential component of an efficacious vaccine. Cervarix is a prophylactic vaccine against human papilloma virus (HPV) types 16 and 18, which can cause cervical cancer, and recently received approval from the FDA, due in part to the protective immunity it conferred against not only HPV types contained in the vaccine but in addition to oncogenic HPV strains that were not contained in the vaccine. Cervarix is formulated with MPL (monophosphoryl lipid A), a TLR-4 targeted adjuvant shown to promote immune response broadening. The recent FDA approvals of these pioneering vaccines are landmark events, and will likely usher in renewed interest and investment in the development of new therapeutic cancer vaccine candidates. In this review, we examine new molecularly defined adjuvants and formulations and its application to cancer vaccines under development.
Collapse
Affiliation(s)
- Thomas W Dubensky
- Immune Design Corporation, 1124 Columbia St., Ste. 700, Seattle, WA 98104, United States
| | | |
Collapse
|